156 related articles for article (PubMed ID: 10450523)
1. Autoaggression and tumor rejection: it takes more than self-specific T-cell activation.
Ganss R; Limmer A; Sacher T; Arnold B; Hämmerling GJ
Immunol Rev; 1999 Jun; 169():263-72. PubMed ID: 10450523
[TBL] [Abstract][Full Text] [Related]
2. Failure to induce organ-specific autoimmunity by breaking of tolerance: importance of the microenvironment.
Limmer A; Sacher T; Alferink J; Kretschmar M; Schönrich G; Nichterlein T; Arnold B; Hämmerling GJ
Eur J Immunol; 1998 Aug; 28(8):2395-406. PubMed ID: 9710217
[TBL] [Abstract][Full Text] [Related]
3. Tumor microenvironment can restrict the effectiveness of activated antitumor lymphocytes.
Ganss R; Hanahan D
Cancer Res; 1998 Oct; 58(20):4673-81. PubMed ID: 9788621
[TBL] [Abstract][Full Text] [Related]
4. CpG-ODN-induced inflammation is sufficient to cause T-cell-mediated autoaggression against hepatocytes.
Sacher T; Knolle P; Nichterlein T; Arnold B; Hämmerling GJ; Limmer A
Eur J Immunol; 2002 Dec; 32(12):3628-37. PubMed ID: 12516551
[TBL] [Abstract][Full Text] [Related]
5. Vaccine therapy of established tumors in the absence of autoimmunity.
Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
[TBL] [Abstract][Full Text] [Related]
6. T cell activation and thymic tolerance induction require different adhesion intensities of the CD8 co-receptor.
Knobloch M; Schönrich G; Schenkel J; Malissen M; Malissen B; Schmitt-Verhulst AM; Hämmerling GJ; Arnold B
Int Immunol; 1992 Oct; 4(10):1169-74. PubMed ID: 1489732
[TBL] [Abstract][Full Text] [Related]
7. Spontaneous mammary carcinomas fail to induce an immune response in syngeneic FVBN202 neu transgenic mice.
Kurt RA; Whitaker R; Baher A; Seung S; Urba WJ
Int J Cancer; 2000 Sep; 87(5):688-94. PubMed ID: 10925363
[TBL] [Abstract][Full Text] [Related]
8. A two-step model for the induction of organ-specific autoimmunity.
Limmer A; Sacher T; Alferink J; Nichterlein T; Arnold B; Hämmerling GJ
Novartis Found Symp; 1998; 215():159-67; discussion 167-71, 186-90. PubMed ID: 9760578
[TBL] [Abstract][Full Text] [Related]
9. Transgenic expression of Ly49A on T cells impairs a specific antitumor response.
Brawand P; Lemonnier FA; MacDonald HR; Cerottini JC; Held W
J Immunol; 2000 Aug; 165(4):1871-6. PubMed ID: 10925266
[TBL] [Abstract][Full Text] [Related]
10. Antigen recognition and allogeneic tumor rejection in CD8+ TCR transgenic/RAG(-/-) mice.
Manning TC; Rund LA; Gruber MM; Fallarino F; Gajewski TF; Kranz DM
J Immunol; 1997 Nov; 159(10):4665-75. PubMed ID: 9366389
[TBL] [Abstract][Full Text] [Related]
11. Transgenic models of T-cell self tolerance and autoimmunity.
Miller JF; Morahan G; Slattery R; Allison J
Immunol Rev; 1990 Dec; 118():21-35. PubMed ID: 2079327
[TBL] [Abstract][Full Text] [Related]
12. Organ injury associated with extrathymic induction of immune tolerance in doubly transgenic mice.
Fields LE; Loh DY
Proc Natl Acad Sci U S A; 1992 Jul; 89(13):5730-4. PubMed ID: 1631053
[TBL] [Abstract][Full Text] [Related]
13. Autoimmune tolerance and type 1 (insulin-dependent) diabetes mellitus.
Nossal GJ; Herold KC; Goodnow CC
Diabetologia; 1992 Dec; 35 Suppl 2():S49-59. PubMed ID: 1478378
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of tumor rejection in anti-CD3 monoclonal antibody-treated mice.
Ellenhorn JD; Schreiber H; Bluestone JA
J Immunol; 1990 Apr; 144(7):2840-6. PubMed ID: 1969454
[TBL] [Abstract][Full Text] [Related]
15. Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy.
Wick M; Dubey P; Koeppen H; Siegel CT; Fields PE; Chen L; Bluestone JA; Schreiber H
J Exp Med; 1997 Jul; 186(2):229-38. PubMed ID: 9221752
[TBL] [Abstract][Full Text] [Related]
16. T and B cell tolerance and responses to viral antigens in transgenic mice: implications for the pathogenesis of autoimmune versus immunopathological disease.
Zinkernagel RM; Pircher HP; Ohashi P; Oehen S; Odermatt B; Mak T; Arnheiter H; Bürki K; Hengartner H
Immunol Rev; 1991 Aug; 122():133-71. PubMed ID: 1937540
[TBL] [Abstract][Full Text] [Related]
17. In vivo programming of tumor antigen-specific T lymphocytes from pluripotent stem cells to promote cancer immunosurveillance.
Lei F; Zhao B; Haque R; Xiong X; Budgeon L; Christensen ND; Wu Y; Song J
Cancer Res; 2011 Jul; 71(14):4742-7. PubMed ID: 21628492
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of autoimmunity in the context of T-cell tolerance: insights from natural and transgenic animal model systems.
Siegel RM; Katsumata M; Komori S; Wadsworth S; Gill-Morse L; Jerrold-Jones S; Bhandoola A; Greene MI; Yui K
Immunol Rev; 1990 Dec; 118():165-92. PubMed ID: 2150401
[TBL] [Abstract][Full Text] [Related]
19. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model.
Morales-Kastresana A; Sanmamed MF; Rodriguez I; Palazon A; Martinez-Forero I; Labiano S; Hervas-Stubbs S; Sangro B; Ochoa C; Rouzaut A; Azpilikueta A; Bolaños E; Jure-Kunkel M; Gütgemann I; Melero I
Clin Cancer Res; 2013 Nov; 19(22):6151-62. PubMed ID: 24030703
[TBL] [Abstract][Full Text] [Related]
20. Deletion of high-avidity T cells by thymic epithelium.
Hoffmann MW; Heath WR; Ruschmeyer D; Miller JF
Proc Natl Acad Sci U S A; 1995 Oct; 92(21):9851-5. PubMed ID: 7568231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
